Table 2.

Performance of NAMPT inhibitor in combination in vitro.

Cancer/Cell Lines	Drug Combination	Study Result	Refs.
Fibrosarcoma HT1080	2.5 nM FK-866/GMX-1778 + 200 μM Temozolomide	Decreased cell viability Decreased NAD Increased apoptosis Increased ROS	[58,61]
Glioblastoma MGG119, MGG152, BT142, U251	5/10 nM FK-866/CHS-828 + 100 μM Temozolomide
Ewing Sarcoma TC32, TC71	5 nM Daporinad (FK-866) + 5 nM Niraparib	Decreased cell viability Decreased NAD	[62]
Pancreatic ductal adenocarcinoma PaTu8988t, Panc-1	6.25 nM STF-118804 + 5 nM Gemcitabine	Decreased cell viability	[45]
	6.25 nM STF-118804 + 5 nM Paclitaxel
	6.25 nM STF-118804 + 300 nM Etoposide
Gastric cancer BCG823	1 nM FK-866 + 3 μg/mL 5-Fluorouracil	Decreased cell viability Increased apoptosis	[3]
Non-small cell lung cancer A549, H1299	150 nM Pemetrexed for 48 h + 8 nM GMX-1777 for the next 24 h	Decreased cell viability Decreased ATP Decreased NAD Increased PARP expression	[60]
Triple-negative breast cancer CAL51	10/100 nM FK866 + 0.1/1/10 µM Olaparib	Decreased cell viability Decreased NAD Increased apoptosis	[63]
Leukemia MV4-11	100 nM KPT-9274 + 10 nM Venetoclax	Decreased cell viability Decreased NAD	[64]
Jurkat	10 nM FK-866 + 5/10 μM Etoposide	Decreased cell viability Decreased PARP-1 expression Increased apoptosis	[65]
MOLT-4
OCI/AML3, Mec.1	3 nM APO866 for 48 h + 10 μM verapamil/1 μM Cyclosporin A/10 μM PGP-4008 for the next 48 h	Decreased cell viability Increased apoptosis	[66]
LAMA-84, RPMI-8226	3 nM APO866 for 48 h + 1 μM Cyclosporin A for the next 48 h
Leukemia Jurkat, PEER, H9, Namalwa	0.1/3.2/4 nM APO866 + 0.1/6.3/100 ng/mL TRAIL	Decreased cell viability Decreased ATP Decreased NAD Increased cell death Increased autophagy	[67]
Multiple myeloma RPMI-8226/S, U266, MM1S, MM1R, ANBL6	1 nM/3 nM FK-866 + 5 nM/10 nM Bortezomib	Decreased cell viability Decreased NAD Increased apoptosis	[68]
Waldenström macroglobulinemia BCMW.1, MWCL.1	3 nM FK-866 + 1 μM Ibrutinib	Decreased cell viability Decreased ATP Decreased NAD Increased apoptosis	[64,69]